adsilico: Messaging, Brand and Website for an In Silico Trials Company Ahead of Its Series A
Solution
Medical devices are tested on small trial cohorts and animal models that rarely reflect the full range of patients a device will treat. Women, older patients and ethnic minorities are often under-represented, and animal anatomy does not always predict human outcomes. adsilico, a University of Leeds spinout, uses its Virtual Chimera technology to generate whole populations of virtual anatomies from anonymised clinical imaging data. It then runs physics-based simulations to show manufacturers how a device behaves across that population.
The science is strong but hard to explain, and the category is still young. Search data showed almost no one looks up "in silico clinical trials" or "virtual patients", so the website would never win by being found. Its job was credibility. It had to show regulators, device manufacturers and investors something convincing quickly, and it had to be ready before a Series A announcement and TCT.
Discovery and messaging. We started by interviewing adsilico's chair, an experienced medtech operator. His advice shaped the brief. Lead with regulatory credentials and a real case study, and show the science rather than describe it. We built a full messaging system from that conversation, a competitor review and the founding team's own language, then presented it alongside the brand and website plan.
Brand identity and visual language. Working with our creative partner Relevance Creative, we developed a new brand concept and colour system and a visual style for the science. We rendered adsilico's own simulation files, including beating hearts, mitral valve motion and neurovascular flow, in that style. Every anatomical visual was checked by the founders for accuracy, because the whole proposition depends on representing real patients faithfully.
Website design and build. We designed and built a new single-page site in Webflow with a contact flow. It puts the evidence first, with a mitral valve repair simulation study and a neurovascular flow diverter example, a clinical advisor panel, and a clear walk-through of how a study runs. We ran an Ahrefs baseline before the rebuild and mapped redirects so the site kept its existing backlinks from Physics World, University of Manchester, Northern Gritstone and others. We also gave the team a domain recommendation and flagged privacy policy updates needed for the new form.
Launch support. We reviewed the Series A press release before it went to the investors' agencies, so the announcement and the new site told the same story.
Results
- A new site live in under two weeks. From kick-off in early October to a published site on adsilico.uk on 16 October, in time for the Series A and TCT.
- A messaging system the whole company can use. One clear account of what adsilico does and why it matters, built from the chair's input and now running through the website and press materials.
- The science on show. adsilico's own simulation outputs became the site's visuals, including a mitral repair study showing a 3.2 mm increase in leaflet coaptation and a flow diverter example showing a 66% reduction in aneurysm blood flow.
- A new visual identity. A brand concept and colour system built for a deep tech company that needs to look as rigorous as its work.
- Search equity kept. Redirects mapped from an Ahrefs audit so existing links from academic, investor and trade sources still land.
Reflection
Asking a device manufacturer to trust a simulated patient over a real one is a big ask, and it can't be won with adjectives. Our clinical background meant we could sit with the founders, understand what a change in coaptation length or aneurysm inflow actually tells a regulator, and decide which proof should come first. The chair summed up the brief in one line. Show it, don't say it. So we built the site around adsilico's own simulations and let the evidence do the persuading. adsilico now has a story and a site that match the quality of its science, ready for the conversations that will define the category.
